Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report

Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation. However, the use of osimertinib may result in the development of further resistance, most commonly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Onco Targets Ther
Hauptverfasser: Zhao, Jing, Zou, Ming, Lv, Jinyan, Han, Yingmin, Wang, Guangzhi, Wang, Gang
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2018
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6134962/
https://ncbi.nlm.nih.gov/pubmed/30233215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S170358
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge